192 related articles for article (PubMed ID: 37087882)
1. Repurposing of FDA-approved drugs as dual-acting MAO-B and AChE inhibitors against Alzheimer's disease: An in silico and in vitro study.
Mateev E; Kondeva-Burdina M; Georgieva M; Zlatkov A
J Mol Graph Model; 2023 Jul; 122():108471. PubMed ID: 37087882
[TBL] [Abstract][Full Text] [Related]
2. Coumarin-dithiocarbamate hybrids as novel multitarget AChE and MAO-B inhibitors against Alzheimer's disease: Design, synthesis and biological evaluation.
He Q; Liu J; Lan JS; Ding J; Sun Y; Fang Y; Jiang N; Yang Z; Sun L; Jin Y; Xie SS
Bioorg Chem; 2018 Dec; 81():512-528. PubMed ID: 30245233
[TBL] [Abstract][Full Text] [Related]
3. Latest advances in dual inhibitors of acetylcholinesterase and monoamine oxidase B against Alzheimer's disease.
Zou D; Liu R; Lv Y; Guo J; Zhang C; Xie Y
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2270781. PubMed ID: 37955252
[TBL] [Abstract][Full Text] [Related]
4. Dipropargyl substituted diphenylpyrimidines as dual inhibitors of monoamine oxidase and acetylcholinesterase.
Kumar B; Kumar V; Prashar V; Saini S; Dwivedi AR; Bajaj B; Mehta D; Parkash J; Kumar V
Eur J Med Chem; 2019 Sep; 177():221-234. PubMed ID: 31151057
[TBL] [Abstract][Full Text] [Related]
5. 4,6-Diphenylpyrimidine Derivatives as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase for the Treatment of Alzheimer's Disease.
Kumar B; Dwivedi AR; Sarkar B; Gupta SK; Krishnamurthy S; Mantha AK; Parkash J; Kumar V
ACS Chem Neurosci; 2019 Jan; 10(1):252-265. PubMed ID: 30296051
[TBL] [Abstract][Full Text] [Related]
6. Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
Sterling J; Herzig Y; Goren T; Finkelstein N; Lerner D; Goldenberg W; Miskolczi I; Molnar S; Rantal F; Tamas T; Toth G; Zagyva A; Zekany A; Finberg J; Lavian G; Gross A; Friedman R; Razin M; Huang W; Krais B; Chorev M; Youdim MB; Weinstock M
J Med Chem; 2002 Nov; 45(24):5260-79. PubMed ID: 12431053
[TBL] [Abstract][Full Text] [Related]
7. Identification of Butyrylcholinesterase and Monoamine Oxidase B Targeted Ligands and their Putative Application in Alzheimer's Treatment: A Computational Strategy.
Jabir NR; Rehman MT; Tabrez S; Alserihi RF; AlAjmi MF; Khan MS; Husain FM; Ahmed BA
Curr Pharm Des; 2021; 27(20):2425-2434. PubMed ID: 33634754
[TBL] [Abstract][Full Text] [Related]
8. Ethyl Acetohydroxamate Incorporated Chalcones: Unveiling a Novel Class of Chalcones for Multitarget Monoamine Oxidase-B Inhibitors Against Alzheimer's Disease.
Reeta ; Baek SC; Lee JP; Rangarajan TM; Ayushee ; Singh RP; Singh M; Mangiatordi GF; Nicolotti O; Kim H; Mathew B
CNS Neurol Disord Drug Targets; 2019; 18(8):643-654. PubMed ID: 31550216
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 4-arylcoumarins as potential anti-Alzheimer's disease agents.
Yun Y; Yang J; Miao Y; Wang X; Sun J
Bioorg Med Chem Lett; 2020 Feb; 30(4):126900. PubMed ID: 31882295
[TBL] [Abstract][Full Text] [Related]
10. Multitarget drug design strategy against Alzheimer's disease: Homoisoflavonoid Mannich base derivatives serve as acetylcholinesterase and monoamine oxidase B dual inhibitors with multifunctional properties.
Li Y; Qiang X; Luo L; Yang X; Xiao G; Zheng Y; Cao Z; Sang Z; Su F; Deng Y
Bioorg Med Chem; 2017 Jan; 25(2):714-726. PubMed ID: 27923535
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Sang Z; Wang K; Shi J; Liu W; Tan Z
Eur J Med Chem; 2019 Sep; 178():726-739. PubMed ID: 31229875
[TBL] [Abstract][Full Text] [Related]
12. Pyridoxine-resveratrol hybrids Mannich base derivatives as novel dual inhibitors of AChE and MAO-B with antioxidant and metal-chelating properties for the treatment of Alzheimer's disease.
Yang X; Qiang X; Li Y; Luo L; Xu R; Zheng Y; Cao Z; Tan Z; Deng Y
Bioorg Chem; 2017 Apr; 71():305-314. PubMed ID: 28267984
[TBL] [Abstract][Full Text] [Related]
13. 2-Oxoquinoline-based-thiosemicarbazones as multitargeting neurotherapeutics against Alzheimer's disease: In vitro and in silico studies of MAO and ChE inhibitors.
Basri R; Fatima S; Jalil S; Imran A; Fatima N; Syed A; Bahkali AH; Iqbal J; Shafiq Z
Arch Pharm (Weinheim); 2023 Nov; 356(11):e2300430. PubMed ID: 37718357
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, biological activity, molecular docking, and molecular dynamics of novel benzimidazole derivatives as potential AChE/MAO-B dual inhibitors.
Osmaniye D; Evren AE; Sağlık BN; Levent S; Özkay Y; Kaplancıklı ZA
Arch Pharm (Weinheim); 2022 Mar; 355(3):e2100450. PubMed ID: 34931332
[TBL] [Abstract][Full Text] [Related]
15. Design and discovery of anthranilamide derivatives as a potential treatment for neurodegenerative disorders via targeting cholinesterases and monoamine oxidases.
Zaib S; Khan I; Ali HS; Younas MT; Ibrar A; Al-Odayni AB; Al-Kahtani AA
Int J Biol Macromol; 2024 Jun; 272(Pt 1):132748. PubMed ID: 38821306
[TBL] [Abstract][Full Text] [Related]
16. Exploration of a Library of 3,4-(Methylenedioxy)aniline-Derived Semicarbazones as Dual Inhibitors of Monoamine Oxidase and Acetylcholinesterase: Design, Synthesis, and Evaluation.
Tripathi RK; Rai GK; Ayyannan SR
ChemMedChem; 2016 Jun; 11(11):1145-60. PubMed ID: 27135466
[TBL] [Abstract][Full Text] [Related]
17. Donepezil + propargylamine + 8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer's disease.
Wang L; Esteban G; Ojima M; Bautista-Aguilera OM; Inokuchi T; Moraleda I; Iriepa I; Samadi A; Youdim MB; Romero A; Soriano E; Herrero R; Fernández Fernández AP; Ricardo-Martínez-Murillo ; Marco-Contelles J; Unzeta M
Eur J Med Chem; 2014 Jun; 80():543-61. PubMed ID: 24813882
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, pharmacological study and docking calculations of new benzo[f]coumarin derivatives as dual inhibitors of enzymatic systems involved in neurodegenerative diseases.
Matos MJ; Janeiro P; González Franco RM; Vilar S; Tatonetti NP; Santana L; Uriarte E; Borges F; Fontenla JA; Viña D
Future Med Chem; 2014 Mar; 6(4):371-83. PubMed ID: 24635520
[TBL] [Abstract][Full Text] [Related]
19. First Synthesis of Racemic
Guieu B; Lecoutey C; Legay R; Davis A; Sopkova de Oliveira Santos J; Altomare CD; Catto M; Rochais C; Dallemagne P
Molecules; 2020 Dec; 26(1):. PubMed ID: 33375412
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of 3,4-dihydro-2(1H)-quinoline-O-alkylamine derivatives as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
Sang Z; Pan W; Wang K; Ma Q; Yu L; Liu W
Bioorg Med Chem; 2017 Jun; 25(12):3006-3017. PubMed ID: 28487125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
